
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About
Denali Therapeutics Inc (DNLI)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/07/2025: DNLI (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -34.63% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.01B USD | Price to earnings Ratio - | 1Y Target Price 40 |
Price to earnings Ratio - | 1Y Target Price 40 | ||
Volume (30-day avg) 936988 | Beta 1.39 | 52 Weeks Range 14.56 - 33.33 | Updated Date 02/10/2025 |
52 Weeks Range 14.56 - 33.33 | Updated Date 02/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.76 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.81% | Return on Equity (TTM) -35.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2418214134 | Price to Sales(TTM) 3339.01 |
Enterprise Value 2418214134 | Price to Sales(TTM) 3339.01 | ||
Enterprise Value to Revenue 2843.16 | Enterprise Value to EBITDA -8.66 | Shares Outstanding 143922000 | Shares Floating 130113783 |
Shares Outstanding 143922000 | Shares Floating 130113783 | ||
Percent Insiders 9.68 | Percent Institutions 90.85 |
AI Summary
Denali Therapeutics Inc. - Comprehensive Overview
Company Profile
History and Background: Founded in 2015, Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing treatments for neurodegenerative diseases. Denali utilizes a deep understanding of genetic, neuronal, and translational biology to develop novel therapeutics.
Core Business Areas:
- Gene Therapy: Denali utilizes this technology to develop treatments targeting the central nervous system (CNS).
- Small Molecule Therapeutic Development: Denali focuses on developing small molecules that modulate key biological pathways in neurodegenerative diseases.
Leadership and Structure: Denali boasts a seasoned leadership team with extensive experience in the biopharmaceutical industry. Some key members include:
- Chief Executive Officer: Ryan Watts
- President: Jörn Drasen
- Chief Development Officer: Harald Hampel
Top Products and Market Share:
- DNL310: An anti-LINGO-1 antibody in Phase I/II trials for hereditary transthyretin amyloidosis (hATTR) with polyneuropathy.
- DNL151: An anti-LRP1 antisense oligonucleotide in Phase I/II trials for Alzheimer's disease.
- DNL254: A small molecule tyrosine kinase inhibitor in preclinical development for Parkinson's disease.
Market Share: Denali's products are currently in research and development phases, and therefore, do not hold a market share in the commercial space.
Product Performance and Market Reception:
- DNL310: Early clinical data shows potential benefit in reducing nerve damage in hATTR patients.
- DNL151: Initial data suggests encouraging safety and tolerability profile.
- DNL254: Preclinical data demonstrates target engagement and potential reduction of alpha-synuclein toxicity.
Total Addressable Market:
- Global Neurodegenerative Disease Market: Estimated to reach $94.9 billion by 2026.
- US Neurodegenerative Disease Market: Projected to reach $44.1 billion by 2026.
Financial Performance:
- Revenue: No current product offerings, therefore, no revenue generated.
- Net Income: Denali currently operates at a net loss due to research and development expenses.
- Profit Margins: Not applicable at this stage as the company is pre-revenue.
- Earnings per Share (EPS): Not applicable as the company is pre-revenue.
Year-over-Year Financial Performance: As a development-stage company, Denali's financial performance is primarily driven by research and development investments. Over the past year, R&D expenses have increased significantly as the company progresses its pipeline candidates.
Cash Flow and Balance Sheet Health: Denali has a strong cash position resulting from its initial public offering and subsequent financing rounds. The company is actively managing expenses to extend its cash runway.
Dividends and Shareholder Returns:
- Dividend History: Denali does not currently pay dividends.
- Shareholder Returns: As a pre-revenue company, Denali's stock price primarily reflects investors' expectations for future success. Shareholder returns have been impacted by market volatility and the evolving drug development landscape.
Growth Trajectory:
- Historical Growth: Since its inception, Denali has demonstrated strong execution advancing its pipeline and securing partnerships.
- Future Growth Projections: The company’s future growth will be driven by the success of its clinical trials and potential commercialization of its drug candidates.
- Recent Initiatives: Denali continues to invest in research and development, expand its product pipeline, and pursue strategic collaborations.
Market Dynamics:
- Industry Trends: Rising prevalence of neurodegenerative diseases, increasing focus on genetic targets, and technological advancements in drug discovery
- Denali's Positioning: Denali is well-positioned with its innovative approach targeting novel pathways and leveraging deep biological understanding.
- Adaptability: The company maintains a flexible and adaptable approach, focusing on areas with high medical need and adjusting strategies based on market and scientific insights.
Competitors:
- Ionis Pharmaceuticals (IONS)
- Biogen Inc. (BIIB)
- Alnylam Pharmaceuticals (ALNY)
- Roche Holding AG (RHHBY)
Market Share Comparison: Denali's competitors hold varying market shares in different neurodegenerative disease segments. As Denali's products are not yet commercialized, it does not have a direct market share comparison.
Competitive Advantages:
- Unique Focus: Targeting gene therapy and small molecules sets Denali apart from many competitors.
- Deep Scientific Expertise: Denali's team has extensive experience in neuroscience and drug development.
- Strong Partnerships: Denali has strategic collaborations with leading research institutions and pharmaceutical companies.
Competitive Disadvantages:
- Pre-Revenue Stage: Denali faces uncertainty associated with the clinical development process.
- Limited Historical Data: Investors must rely on future expectations rather than historical performance.
- Competition in Niche Markets: Denali operates in highly competitive therapeutic areas.
Potential Challenges and Opportunities:
Key Challenges:
- Clinical Trial Success: Denali's future hinges on successful completion of臨床試驗和 regulatory approval.
- Market Adoption: Even with successful products, achieving market acceptance within crowded therapeutic landscapes can be challenging.
- Competition: Denali faces numerous competitors with more established pipelines and commercial offerings.
Potential Opportunities:
- Large Addressable Market: The substantial market size for neurodegenerative diseases presents significant revenue potential.
- Unmet Medical Needs: Addressing major unmet medical needs with novel therapies could lead to significant market impact.
- Strategic Partnerships: Denali's collaborations could accelerate development, commercialization, and market access.
Recent Acquisitions:
- None in the past 3 years.
AI-Based Fundamental Rating:
- Rating: 7/10
- Justification: Denali possesses compelling science, a promising pipeline, and a solid leadership team. However, the company's pre-revenue status and reliance on clinical trial outcomes introduce significant risk.
Sources:
- Denali Therapeutics website
- Securities and Exchange Commission (SEC) filings
- Market research reports
- Company presentations
Disclaimer: This information is for educational purposes only and should not be considered financial advice. Investors should conduct their own research and due diligence before making investment decisions.
About Denali Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2017-12-08 | Co-Founder, President, CEO & Director Dr. Ryan J. Watts Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 390 | |
Full time employees 390 |
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.